Analyst Upgrades: Abeona Therapeutics Inc, Twitter Inc, and Hewlett Packard Enterprise Co

Analysts upwardly revised their ratings and price targets on Abeona Therapeutics Inc (ABEO), Twitter Inc (TWTR), and Hewlett Packard Enterprise Co (HPE)

by Kirra Fedyszyn

Published on Sep 8, 2016 at 10:22 AM

Analysts are weighing in on biotech issue Abeona Therapeutics Inc (NASDAQ:ABEO), microblogging concern Twitter Inc (NYSE:TWTR), and tech stock Hewlett Packard Enterprise Co (NYSE:HPE). Here's a quick roundup of today's bullish brokerage notes on ABEO, TWTR, and HPE.

  • ABEO is up 5.2% at $5.04, after Cantor Fitzgerald began coverage on the stock with an upbeat "buy" rating and a $21 price target, representing a level the shares haven't seen in more than two years. Also boosting Abeona Therapeutics Inc this morning is news the company has enrolled a fifth patient in its Phase 1/2 trial of its treatment for recessive dystrophic epidermolysis bullosa (RDEB) -- which has demonstrated "promising clinical efficacy." The stock has been on a tear since early July, more than doubling in value, and bringing its year-to-date lead to 50%. Analysts are firmly on board, too, with all three brokerage firms tracking the stock maintaining a "strong buy" rating
  • TWTR received a price-target hike to $23 from $21 at Goldman Sachs, but it's not having the effect a recent batch of options bulls were hoping for. In fact, the stock is off 5.3% at $18.82, as the company prepares for a board meeting today where a sale could be discussed. And though CEO Jack Dorsey's job is not expected to be on the line, sources have said he may have just a few more quarters to turn around Twitter Inc. While the shares have been making a comeback in recent months, TWTR is still down more than 30% year-over-year. It seems analysts don't have high expectations, either, as 22 out of 26 rate the stock a "hold" or worse. 
  • HPE is off 2% at $21.64, despite better-than-expected fiscal third-quarter earnings, and following an announcement it will spin off part of its software business in a deal with U.K.-based Micro Focus International totaling $8.8 billion. The news has been met with a slew of brokerage attention, including no fewer than eight price-target hikes -- including an increase to $27 at Jefferies. However, Wells Fargo broke from the pack, downgrading Hewlett Packard Enterprise Co to "market perform" from "outperform," citing a lack of near-term catalysts. Regardless, the shares are up over 42% year-to-date, and short sellers have been backing off in recent weeks, with short interest falling by 21.4% over the two most recent reporting periods. But these pessimistic positions still account for a week's worth of trading, at HPE's typical daily pace. 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.